Cite
Hagerty B, O'Sullivan TN, Zhang X, et al. Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. Mol Cancer Ther. 2021;20(10):2082-2092doi: 10.1158/1535-7163.MCT-21-0017.
Hagerty, B., O'Sullivan, T. N., Zhang, X., Collins, N. K., Custer Lawrence, W., Bassel, L. L., Pate, N., Xu, J., Guerin, T. M., Kozlov, S., & Alewine, C. (2021). Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. Molecular cancer therapeutics, 20(10), 2082-2092. https://doi.org/10.1158/1535-7163.MCT-21-0017
Hagerty, Brendan, et al. "Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers." Molecular cancer therapeutics vol. 20,10 (2021): 2082-2092. doi: https://doi.org/10.1158/1535-7163.MCT-21-0017
Hagerty B, O'Sullivan TN, Zhang X, Collins NK, Custer Lawrence W, Bassel LL, Pate N, Xu J, Guerin TM, Kozlov S, Alewine C. Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. Mol Cancer Ther. 2021 Oct;20(10):2082-2092. doi: 10.1158/1535-7163.MCT-21-0017. Epub 2021 Jul 26. PMID: 34315768; PMCID: PMC8492545.
Copy
Download .nbib